Ramucirumab plus paclitaxel as second-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma: a nationwide real-world outcomes in Korea study (KCSG-ST19-16)

BACKGROUND: Ramucirumab as monotherapy or in combination with paclitaxel is a second-line treatment option recommended for patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma. However, real-world data from large study cohorts focused on...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Hye Sook, Kim, Bum Jun, Jee, Hee-Jung, Ryu, Min-Hee, Park, Se Hoon, Rha, Sun Young, Kim, Jong Gwang, Bae, Woo Kyun, Lee, Keun-Wook, Oh, Do-Youn, Kim, In-Ho, Sym, Sun Jin, Oh, So Yeon, Kim, Hyeong Su, Byun, Ji-Hye, Kim, Dong Sook, Suh, Young Ju, An, Hyonggin, Zang, Dae Young
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8450614/
https://www.ncbi.nlm.nih.gov/pubmed/34552667
http://dx.doi.org/10.1177/17588359211042812

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8450614/
https://www.ncbi.nlm.nih.gov/pubmed/34552667
http://dx.doi.org/10.1177/17588359211042812

Ejemplares similares